Stock data
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE) reported revenue of US$0.00M and net income of -US$155.20M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$0.00M | — | -US$209.56M | -US$155.20M | — |
| 2024 | US$0.00M | — | -US$208.57M | -US$208.02M | — |
| 2023 | US$0.89M | — | -US$242.30M | -US$338.79M | — |
| 2022 | US$2.33M | — | -US$84.78M | -US$83.81M | — |
| 2021 | US$18.74M | — | -US$65.65M | -US$65.80M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$36.20M | — |
| 2026-03-31 | — | -US$69.00M | — |
| 2025-12-31 | — | -US$62.53M | — |
| 2025-09-30 | — | -US$11.18M | — |
| 2025-06-30 | — | -US$36.72M | — |
| 2025-03-31 | — | -US$44.77M | — |
| 2024-12-31 | US$0.00M | -US$56.30M | — |
| 2024-09-30 | US$0.00M | -US$69.03M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.